Last week, we participated in the Business-7 (B7) Summit, hosted by our French counterparts from the Mouvement des entreprises de […]
Pharmacare: Raising the Bar for Canadians
Over the past few months, we have been asking our members about their thoughts on national pharmacare. The consensus is clear: employers agree that a national pharmacare program should raise the bar for Canadians and improve health outcomes.
Employers wholeheartedly believe in the distinctly Canadian value that no one in this country should lack access to the medicines they need. However, the fact is that most Canadians find the current system is working and they are satisfied with their existing coverage.
86% of Canadians are satisfied that their private/group insurance is making medicine affordable and 82% are satisfied with the range of medicines covered. Overall, 77% of Canadians say that the medicines they need are affordable or “affordable enough.” Among those Canadians who received a prescription in the preceding six months, less than 1% indicated that they did not take their medication as prescribed because of cost.
Approximately 10% of Canadians are uninsured or underinsured and 75% of Canadians believe it is quite or very important that “government shouldn’t spend on those who already have prescription drug coverage”. Our members agree that it’s not fiscally prudent to increase public sector debt to pay for a costly single-payer system when the existing system is working for most Canadians.
We believe that national pharmacare should provide the most appropriate coverage to those who need it. A national pharmacare program should ensure that Canadians have access to the best and most innovative medicines and health technologies. Perhaps most importantly for the health outcomes of Canadians, we need to ensure that a national pharmacare program does not reduce the coverage enjoyed by most Canadians under the existing system or result in coverage falling to the lowest common denominator. If the government is to move forward with a national pharmacare program, it must give Canadians an advantage over what the system currently offers.
To read our full response to the pharmacare consultation, click here.
As published on Lilly Canada’s LillyPadCA blog.